Glurazyme (imiglucerase biosimilar) / Generium, Ligand - LARVOL DELTA

Results of a prospective observational study of imiglucerase biosimilar in adults with type I Gaucher disease (PubMed, Ter Arkh) - "Long-term therapy with the imiglucerase biosimilar was associated with a stable course of GD without progression. It was characterized by a good safety profile and low immunogenicity."

Journal • Observational data • Gaucher Disease • Genetic Disorders • Hematological Disorders • Metabolic Disorders • Type 1 Gaucher Disease